Cerveau Technologies, Inc. announces Formation of Scientific Advisory Board

Cerveau Technologies, Inc. today announced formation of its Scientific Advisory Board (SAB), comprised of top tier physicians and scientists from around the globe, spanning areas of expertise from chemistry, biology to medicine associated with the assessment and ultimate treatment of neurodegenerative diseases, such as Alzheimer’s Disease.

 

Cerveau Scientific Advisory Board Virtual Conference 2020

MK-6240 Users Group Meeting | Webinar #1 by Cerveau Technologies Inc
2020 Virtual Conference with world renowned Leaders and Scientists in the industry!

Rick Hiatt (Cerveau Technologies)
Oskar Hannson (Lund University)
Pedro Rosa-Neto (McGill University)
Keith Johnson (Harvard University)
Kuang Gong (Harvard University)
Christopher Rowe (University of Melbourne)
See the conference here

Cerveau Technologies, Inc. Announces Collaboration with Alector, Inc.

BOSTON–(BUSINESS WIRE)–Cerveau Technologies Inc. today announced a licensing agreement with Alector, in which Cerveau will provide its investigational imaging agent (MK-6240) to Alector for use in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs, made up of aggregated tau protein, are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.

Cerveau Technologies Inc. Signs Research Agreement with Takeda to Provide Novel Tau Imaging Agent

BOSTON–(BUSINESS WIRE)–Cerveau Technologies, Inc. today announced a research collaboration agreement with Takeda Pharmaceutical Company Limited (Takeda), which will enable Takeda to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.

Cerveau Technologies, Inc. Signs Research Agreement with Kobe City Hospital Organisation, Japan

BOSTON–(BUSINESS WIRE)–Cerveau Technologies Inc. today announced an agreement with the Kobe City Hospital Organisation in Japan to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.

Cerveau Technologies, Inc. Signs Research Agreement with the University of Washington

BOSTON–(BUSINESS WIRE)–Cerveau Technologies Inc. today announced an agreement with the University of Washington to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.

Cerveau Technologies Inc. Signs License and Supply Agreement with AbbVie for Novel Tau Imaging Agent

BOSTON–(BUSINESS WIRE)– Cerveau Technologies Inc. today announced a license and supply agreement with AbbVie for use of [F-18]MK-6240, an investigational imaging agent to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain.

Cerveau Technologies, Inc. Signs Research Agreement with Columbia University Medical Center

BOSTON–(BUSINESS WIRE)–Cerveau Technologies Inc. today announced an agreement with Columbia University Medical Center in New York, New York to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.

Cerveau Technologies Inc. Signs Collaboration Agreement with Janssen for Novel Tau Imaging Agent

BOSTON–(BUSINESS WIRE)–Cerveau Technologies, Inc. today announced a research collaboration agreement with Janssen Pharmaceuticals, Inc. for use of [F-18]MK-6240, an investigational imaging agent to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs, which are made up of aggregated tau protein, are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.